Ventoux Biosciences

Menu

Biopharmaceutical Company of the Year

Ventoux Biosciences Biopharmaceutical Company of the Year

Ventoux Biosciences Recognized as Biopharmaceutical Company of the Year

We are honored and excited to share that Ventoux Biosciences has received the award for Biopharmaceutical Company of the Year (2023/24) by Corporate LiveWire Global Awards.

The recognition of our mission, progress, and the team is greatly appreciated. Our ultimate goal has always been, and will continue to be, to develop and deliver innovative treatments that significantly impact the lives of Dupuytren’s and fibrosis patients. Awards are a testament to our efforts, but our true satisfaction comes from knowing that our work contributes to our goal of improving patient care and outcomes.

Global Awards Article

Ventoux Biosciences Inc. aims to develop and market innovative non-surgical therapies to slow disease progression and enhance patient outcomes. Founded in 2022 by Kurt Harrington, a patient suffering from the chronic disease, Dupuytren’s, the 25 + year veteran of the biotech and pharmaceutical industry hopes to help alleviate the debilitating symptoms of this condition, as well as Ledderhose disease and other related fibrotic conditions. Current treatments are very limited and often leave patients with a difficult choice of either undergoing invasive surgery or simply waiting for breakthroughs in the field. Ventoux is a patient-focused organisation dedicated to addressing these unmet needs, working on frontline, disease-modifying treatments for early to moderate stages alongside complementary options to reduce recurrence.

The biopharmaceutical experts employ forward-thinking strategies, utilising drug repurposing and reformulation to accelerate the development of safe and effective solutions.

One of their standout achievements is the meticulous selection of key compounds for evaluation. Through rigorous scientific assessments, expert input and cutting-edge Al analysis, Ventoux is paving the way towards breakthrough treatments. The preclinical assessments are specifically designed to target fibrosis, offering hope to those affected by these chronic, progressive conditions. Based in San Diego, Ventoux Biosciences operates as a privately held Delaware C-Corp, with a sharp focus on acquiring, in-licensing, developing and commercialising proprietary products for Dupuytren’s disease, Ledderhose disease and related fibroproliferative, inflammatory conditions, placing them at the forefront of biopharmaceutical innovation.

The judging panel was particularly impressed by Ventoux Biosciences focus on patient-centred care, which is not limited to individuals in the United States. Their extensive involvement with patients across the globe underscores the immense medical demand for effective treatments and by listening to the voices and experiences of those directly impacted, Ventoux Biosciences is guided by the real needs and challenges faced by patients. Their commitment to rigorous scientific assessments and investment in clinical research demonstrates their outstanding contribution to the medical field and the lives of those they aim to serve.

Global Awards Press Announcement

Biopharmaceutical Company of the Year: Ventoux Biosciences

Share:

Categories

Recent Posts

Latha Satish, M.Sc., M.Phil, Ph.D.

Dr. Satish is a trained biotechnologist with several years of experience in cell and molecular biology. Dr. Satish’s interest has been in skin research with a special focus on skin inflammation, infection, and fibrosis. The other arm of Dr. Satish’s research has been to study the molecular determinants of palmar fascial disease, Dupuytren’s contracture.

Her long-term interest has been to develop therapeutic agents to help alleviate the pain and distress of patients with Dupuytren’s. Her studies on Dupuytren’s disease were funded by a private donor, which moved the research forward to study this disease in an animal model, which was not feasible earlier. Dr. Satish’s research on Dupuytren has identified small molecules that can be used as a target to intervene with the progression and development of the disease.

Dr. Satish received her Ph.D. from a prestigious institute in India and did her post-doctoral training at the University of Pittsburgh. Currently, Dr. Satish serves as a faculty at the Division of Asthma Research, Cincinnati Children’s Hospital; named as the top hospital in the US. At Cincinnati Children’s, Dr. Satish researches Atopic Dermatitis, a chronic inflammatory skin disease affecting children and adults. Dr. Satish has published over 50 articles in peer-reviewed journals, review articles and book chapters.

Dr. Keith Denkler

Dr. Denkler is an accomplished, board certified plastic surgeon with expertise in aesthetic and reconstructive surgery. Dr. Denkler is a clinical professor of plastic surgery at UCSF and has a private practice in Marin County.

He is internationally renowned for his use of multiple approaches in treating the debilitating and disabling effects of palmar fibromatosis (Dupuytren disease). Dr. Denkler is an expert in needle aponeurotomy (NA), a minimally invasive procedure that uses subcutaneous needles to release the contracture as well as use of subcutaneous injection of collagenase. He has treated over 10,000 Dupuytren’s fingers, authored >35 publications and book chapters, presented internationally and domestically and is often cited for expert opinion in national and international news discussing Dupuytren’s. HIs pioneering investigational work documenting the safety of epinephrine with local anesthesia contributed to the origination of “wide-awake hand surgery”.

Dr. Denkler trained at prestigious medical institutions in the United States and Europe. He attended Baylor College of Medicine in Houston, Texas, followed by residency training in plastic and reconstructive surgery with the Cronin, Bauer, and Biggs group, also in Houston. Additionally, Dr. Denkler completed a hand surgery fellowship with Dr. Eugene Kilgore in San Francisco and one year of fellowship training in craniofacial surgery with Dr. Paul Tessier in Paris, France.

Dr. daiva bajorunas

Daiva Bajorunas MD is an endocrinologist with more than 25 years of experience in the biopharmaceutical industry.  She has a strong interest in advancing therapeutic options for conditions of significant unmet medical need. 

For the past decade, Daiva has been engaged as a consultant to the pharmaceutical industry, currently as Founder and Principal, DBMD Consulting, and previously as Chief Medical Officer / Chief Scientific Officer for Vault Bioventures. She has provided her expertise to enhance large, mid-size and small pharmaceutical company product development, clinical/regulatory, and life cycle strategies for both drugs and devices, including oral, transdermal, injectable and inhalative delivery systems, working across multiple therapeutic areas and geographies. She has considerable experience chairing Data Safety Monitoring Boards.   

In the past she held various R&D positions of increasing responsibility at Rhone-Poulenc Rorer, BMS, Aventis (acquired by Sanofi), and Kos Pharmaceuticals (acquired by Abbott). Before she joined industry, she held academic appointments at Memorial Sloan-Kettering Cancer Center and Cornell University Medical College (CUMC), and was Director of Clinical Care, Endocrinology Service, Memorial Hospital (MH), New York, NY. Daiva received her MD degree at the University of Michigan Medical School, did her residency training at St. Vincent’s Hospital & Medical Center in NY, her metabolism fellowship at Stanford University Medical Center, CA and her endocrinology fellowship at MH/CUMC, NY.